When survival was analyzed in the four subgroups classified according to FOXP3 localization in tumor cells (−/−, +/−, −/+ and +/+, cytoplasm/nucleus FOXP3 expression), positive patients with either cytoplasmic or nuclear FOXP3 staining were found to have a similar, worse, or improved outcome compared to the negative (−/−) group (data not shown). The gene discussed is FOXP3; the disease is neoplasm.